Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 3
1989 2
1990 3
1991 5
1992 5
1993 7
1994 5
1995 6
1996 3
1997 6
1998 6
1999 8
2000 1
2001 5
2002 5
2003 2
2004 9
2005 4
2006 5
2007 8
2008 17
2009 20
2010 19
2011 18
2012 22
2013 21
2014 40
2015 34
2016 54
2017 57
2018 64
2019 73
2020 100
2021 116
2022 104
2023 112
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

912 results

Results by year

Filters applied: . Clear all
Page 1
CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.
Wen J, Wang S, Guo R, Liu D. Wen J, et al. Eur J Med Chem. 2023 Jan 5;245(Pt 1):114884. doi: 10.1016/j.ejmech.2022.114884. Epub 2022 Oct 29. Eur J Med Chem. 2023. PMID: 36335744 Review.
Mutations of CSF1R have been implicated in neurodegeneration, skeletal anomalies, and cancers. ...Herein, we've comprehensively reviewed the latest progression of CSF1R inhibitors under clinical and preclinical studies. Key findings of CSF1R targeted t …
Mutations of CSF1R have been implicated in neurodegeneration, skeletal anomalies, and cancers. ...Herein, we've comprehensivel …
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy.
Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Cannarile MA, et al. J Immunother Cancer. 2017 Jul 18;5(1):53. doi: 10.1186/s40425-017-0257-y. J Immunother Cancer. 2017. PMID: 28716061 Free PMC article. Review.
We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies. Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impac …
We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive over …
Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer.
Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O'Brien SA, He Y, Wang L, Zhang Q, Kim A, Gao R, Orf J, Wang T, Sawant D, Kang J, Bhatt D, Lu D, Li CM, Rapaport AS, Perez K, Ye Y, Wang S, Hu X, Ren X, Ouyang W, Shen Z, Egen JG, Zhang Z, Yu X. Zhang L, et al. Cell. 2020 Apr 16;181(2):442-459.e29. doi: 10.1016/j.cell.2020.03.048. Cell. 2020. PMID: 32302573 Free article.
We performed scRNA-seq analyses on immune and stromal populations from colorectal cancer patients, identifying specific macrophage and conventional dendritic cell (cDC) subsets as key mediators of cellular cross-talk in the tumor microenvironment. Defining comparable myelo …
We performed scRNA-seq analyses on immune and stromal populations from colorectal cancer patients, identifying specific macrophage an …
Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer.
Buechler MB, Fu W, Turley SJ. Buechler MB, et al. Immunity. 2021 May 11;54(5):903-915. doi: 10.1016/j.immuni.2021.04.021. Immunity. 2021. PMID: 33979587 Free article. Review.
Here, we review the current understanding of the molecular mechanisms that underlie fibroblast-macrophage interactions in health, fibrosis, and cancer. We present an integrated view of fibroblast-macrophage interactions that is centered on the CSF1-CSF1R axis and di …
Here, we review the current understanding of the molecular mechanisms that underlie fibroblast-macrophage interactions in health, fibrosis, …
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG. Zhu Y, et al. Cancer Res. 2014 Sep 15;74(18):5057-69. doi: 10.1158/0008-5472.CAN-13-3723. Epub 2014 Jul 31. Cancer Res. 2014. PMID: 25082815 Free PMC article.
Cancer immunotherapy generally offers limited clinical benefit without coordinated strategies to mitigate the immunosuppressive nature of the tumor microenvironment. ...Investigations of this response revealed that CSF1R blockade also upregulated T-cell checkpoint m …
Cancer immunotherapy generally offers limited clinical benefit without coordinated strategies to mitigate the immunosuppressive natur …
Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1.
Cai H, Zhang Y, Wang J, Gu J. Cai H, et al. Front Immunol. 2021 Jun 23;12:690869. doi: 10.3389/fimmu.2021.690869. eCollection 2021. Front Immunol. 2021. PMID: 34248982 Free PMC article. Review.
Targeting CSF1/CSF1R for M2 macrophage reprogramming has been widely performed in clinical trials for cancer therapy. ...Macrophage reprogramming or PD-L1/PD-1 blockade alone is less effective in the treatment of most cancers. Since PD-L1/PD-1 blockade could …
Targeting CSF1/CSF1R for M2 macrophage reprogramming has been widely performed in clinical trials for cancer therapy. ...Macro …
Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy.
Cao X, Chen J, Li B, Dang J, Zhang W, Zhong X, Wang C, Raoof M, Sun Z, Yu J, Fakih MG, Feng M. Cao X, et al. Sci Adv. 2022 Mar 18;8(11):eabl9171. doi: 10.1126/sciadv.abl9171. Epub 2022 Mar 18. Sci Adv. 2022. PMID: 35302839 Free PMC article.
We identified paclitaxel as a universal adjuvant that efficiently potentiated ADCP by a variety of anticancer antibodies in multiple cancers. Rather than eliciting cytotoxicity on cancer cells, paclitaxel polarized macrophages toward a state with enhanced phagocytic …
We identified paclitaxel as a universal adjuvant that efficiently potentiated ADCP by a variety of anticancer antibodies in multiple canc …
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M. Katoh M. Int J Mol Med. 2016 Jul;38(1):3-15. doi: 10.3892/ijmm.2016.2620. Epub 2016 May 31. Int J Mol Med. 2016. PMID: 27245147 Free PMC article. Review.
FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer. BCR-FGFR1, CNTRL-FGFR1, CUX1-FGFR1, FGFR1OP-FGFR1, MYO18A-FGFR1 and ZMYM2-FGFR1 fusions in myeloproliferative neoplasms are non-receptor-type FG …
FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer. BCR-FGFR1, …
Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages.
Zhu M, Bai L, Liu X, Peng S, Xie Y, Bai H, Yu H, Wang X, Yuan P, Ma R, Lin J, Wu L, Huang M, Li Y, Luo Y. Zhu M, et al. J Immunother Cancer. 2022 Dec;10(12):e005610. doi: 10.1136/jitc-2022-005610. J Immunother Cancer. 2022. PMID: 36600555 Free PMC article.
BACKGROUND: Colony-stimulating factor 1 receptor (CSF1R), a classic tyrosine kinase receptor, has been identified as a proto-oncogene in multiple cancers. ...However, we found here that the CSF1R expression was abnormally down-regulated in colorectal cance …
BACKGROUND: Colony-stimulating factor 1 receptor (CSF1R), a classic tyrosine kinase receptor, has been identified as a proto-oncogene …
Cancer-Associated Fibroblasts Neutralize the Anti-tumor Effect of CSF1 Receptor Blockade by Inducing PMN-MDSC Infiltration of Tumors.
Kumar V, Donthireddy L, Marvel D, Condamine T, Wang F, Lavilla-Alonso S, Hashimoto A, Vonteddu P, Behera R, Goins MA, Mulligan C, Nam B, Hockstein N, Denstman F, Shakamuri S, Speicher DW, Weeraratna AT, Chao T, Vonderheide RH, Languino LR, Ordentlich P, Liu Q, Xu X, Lo A, Puré E, Zhang C, Loboda A, Sepulveda MA, Snyder LA, Gabrilovich DI. Kumar V, et al. Cancer Cell. 2017 Nov 13;32(5):654-668.e5. doi: 10.1016/j.ccell.2017.10.005. Cancer Cell. 2017. PMID: 29136508 Free PMC article.
Tumor-associated macrophages (TAM) contribute to all aspects of tumor progression. Use of CSF1R inhibitors to target TAM is therapeutically appealing, but has had very limited anti-tumor effects. ...Combining CSF1R inhibitor with a CXCR2 antagonist blocked granulocy …
Tumor-associated macrophages (TAM) contribute to all aspects of tumor progression. Use of CSF1R inhibitors to target TAM is therapeut …
912 results